Oncology Overview: Selpercatinib in the Treatment of Medullary Thyroid Cancer
June 17th 2022Selpercatinib (Retevmo, Loxo Oncology) is FDA-approved to treat 3 types of tumors—metastatic RET fusion-positive non-small cell lung cancer, advanced medullary thyroid cancer (MTC) or MTC that has spread, and advanced RET fusion-positive thyroid cancer.
Read More